48 related articles for article (PubMed ID: 23658296)
1. Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.
Molina-Arcas M; Moore C; Rana S; van Maldegem F; Mugarza E; Romero-Clavijo P; Herbert E; Horswell S; Li LS; Janes MR; Hancock DC; Downward J
Sci Transl Med; 2019 Sep; 11(510):. PubMed ID: 31534020
[TBL] [Abstract][Full Text] [Related]
2. Opening a new GATAway for treating KRAS-driven lung tumors.
Barbacid M
Cancer Cell; 2012 May; 21(5):598-600. PubMed ID: 22624710
[TBL] [Abstract][Full Text] [Related]
3. A meta-analysis of lung cancer gene expression identifies PTK7 as a survival gene in lung adenocarcinoma.
Chen R; Khatri P; Mazur PK; Polin M; Zheng Y; Vaka D; Hoang CD; Shrager J; Xu Y; Vicent S; Butte AJ; Sweet-Cordero EA
Cancer Res; 2014 May; 74(10):2892-902. PubMed ID: 24654231
[TBL] [Abstract][Full Text] [Related]
4. A rare population of CD24(+)ITGB4(+)Notch(hi) cells drives tumor propagation in NSCLC and requires Notch3 for self-renewal.
Zheng Y; de la Cruz CC; Sayles LC; Alleyne-Chin C; Vaka D; Knaak TD; Bigos M; Xu Y; Hoang CD; Shrager JB; Fehling HJ; French D; Forrest W; Jiang Z; Carano RA; Barck KH; Jackson EL; Sweet-Cordero EA
Cancer Cell; 2013 Jul; 24(1):59-74. PubMed ID: 23845442
[TBL] [Abstract][Full Text] [Related]
5. Emerging strategies to target RAS signaling in human cancer therapy.
Chen K; Zhang Y; Qian L; Wang P
J Hematol Oncol; 2021 Jul; 14(1):116. PubMed ID: 34301278
[TBL] [Abstract][Full Text] [Related]
6. Targeting the Tumor Microenvironment: An Unexplored Strategy for Mutant KRAS Tumors.
Dias Carvalho P; Machado AL; Martins F; Seruca R; Velho S
Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31847096
[TBL] [Abstract][Full Text] [Related]
7. Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer.
Hamilton N; Austin D; Márquez-Garbán D; Sanchez R; Chau B; Foos K; Wu Y; Vadgama J; Pietras R
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29099049
[TBL] [Abstract][Full Text] [Related]
8. Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR.
Richer AL; Friel JM; Carson VM; Inge LJ; Whitsett TG
Pharmgenomics Pers Med; 2015; 8():63-79. PubMed ID: 25897257
[TBL] [Abstract][Full Text] [Related]
9. A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours.
Wilky BA; Rudek MA; Ahmed S; Laheru DA; Cosgrove D; Donehower RC; Nelkin B; Ball D; Doyle LA; Chen H; Ye X; Bigley G; Womack C; Azad NS
Br J Cancer; 2015 Jan; 112(1):24-31. PubMed ID: 25268371
[TBL] [Abstract][Full Text] [Related]
10. Selumetinib in advanced non small cell lung cancer (NSCLC) harbouring KRAS mutation: endless clinical challenge to KRAS-mutant NSCLC.
Paolo M; Assunta S; Antonio R; Claudia SP; Anna BM; Clorinda S; Francesca C; Fortunato C; Cesare G
Rev Recent Clin Trials; 2013 Jun; 8(2):93-100. PubMed ID: 24063423
[TBL] [Abstract][Full Text] [Related]
11. The genetics and biology of KRAS in lung cancer.
Westcott PM; To MD
Chin J Cancer; 2013 Feb; 32(2):63-70. PubMed ID: 22776234
[TBL] [Abstract][Full Text] [Related]
12. Two is better than one: combining IGF1R and MEK blockade as a promising novel treatment strategy against KRAS-mutant lung cancer.
Chen R; Sweet-Cordero EA
Cancer Discov; 2013 May; 3(5):491-3. PubMed ID: 23658296
[TBL] [Abstract][Full Text] [Related]
13. Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer.
Molina-Arcas M; Hancock DC; Sheridan C; Kumar MS; Downward J
Cancer Discov; 2013 May; 3(5):548-63. PubMed ID: 23454899
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.
Sunaga N; Kaira K; Imai H; Shimizu K; Nakano T; Shames DS; Girard L; Soh J; Sato M; Iwasaki Y; Ishizuka T; Gazdar AF; Minna JD; Mori M
Oncogene; 2013 Aug; 32(34):4034-42. PubMed ID: 22964644
[TBL] [Abstract][Full Text] [Related]
15. BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
Ku BM; Jho EH; Bae YH; Sun JM; Ahn JS; Park K; Ahn MJ
Invest New Drugs; 2015 Feb; 33(1):12-21. PubMed ID: 25342139
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
